Shares of Aegerion Pharmaceuticals hit a new 52-week high in intra-day trading on Friday. The company hadn't announced any information about its lead drug lomitapide. But a potential competitor from Isisand Sanofi received a negative recommendation from a European Medicines Agency committee, citing safety concerns. This bump was temporary, but the EMA info adds to past events to spell trouble for Kynamro -- and a potential win for Aegerion.
Lomitapide and Kynamro treat homozygous familial hypercholesterolemia (HoFH) -- or severely high cholesterol. The drugs have run nearly parallel down the pipelines, making an event for one reflect almost immediately upon the other. And the drugs have both proven effective , meaning the final battle panel will play out in the arena of safety.
It's a battle that Kynamro may lose. The drug's latest setback is the EMA committee "nay." Safety concerns aren't surprising; both drugs have faced safety questions along the way. But a Kynamro-specific concern could become the decider.
Both HoFH drugs went before FDA advisory panels in October, appearing on consecutive days. Aegerion was up first, and shares rose 13% upon the approval recommendation, despite concerns about potential liver risks. Kynamro also received a recommendation, but Isis shares fell 20%, due to additional concerns raised by its panel. As the Fool's Sean Williams wrote, the panel detailed Kynamro's risk of abnormal tissue growth that appeared in 3.1% of the trial's patients.
The time for the FDA's decisions is upon us. Aegerion should receive word by the end of this month, and Isis should come in late January . Investors need to keep a close watch on the results of these decisions.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report, "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Aegerion Hits New High originally appeared on Fool.com.
Brandy Betz has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.